Hyperhomocysteinemia and Neurologic Disorders: a Review

키워드

참고문헌 (97)

1. Maxwell SR, "Coronary artery disease--free radical damage, antioxidant protection and the role of homocysteine", Basic Res Cardiol, 95(1), pp.I65~I71 (2000)
2. Graham IM, "Vitamins, homocysteine and cardiovascular risk", Cardiovasc Drugs Ther, 16, pp.383~389 (2002)
3. Finkelstein JD, "The metabolism of homocysteine: pathways and regulation", Eur J Pediatr, 157(Suppl 2), pp.S40~S44 (1998)
4. Selhub J., "Homocysteine metabolism", Annu Rev Nutr, 19, pp.217~246 (1999)
5. Pietrzik K, "Vitamins B12, B6 and folate as determinants of homocysteine concentration in the healthy population", Eur J Pediatr, 157(Suppl 2), pp.S135~S138 (1998)
6. Huang YC, "The status of plasma homocysteine and related B-vitamins in healthy young vegetarians and nonvegetarians", Eur J Nutr, 42, pp.84~90 (2003)
7. Kulkarni K, "Lifestyle, homocysteine, and the metabolic syndrome", Metab Syndr Relat Disord, 1, pp.141~147 (2003)
8. Stea TH, "Changes in predictors and status of homocysteine in young male adults after a dietary intervention with vegetables, fruits and bread", Eur J Nutr, 47, pp.201~209 (2008)
9. Di Santolo M, "Association of recreational physical activity with homocysteine, folate and lipid markers in young women", Eur J Appl Physiol, 105, pp.111~118 (2009)
10. McMahon JA, "A controlled trial of homocysteine lowering and cognitive performance", N Engl J Med, 354, pp.2764~2772 (2006)
11. Katko M, "Relationship between serum nickel and homocysteine concentration in hemodialysis patients", Biol Trace Elem Res, 124, pp.195~205 (2008)
12. Athyros VG, "Homocysteine: an emerging cardiovascular risk factor that never really made it", Open Clin Chem J, 3, pp.19~24 (2010)
13. Heinecke JW, "Biochemical evidence for a link between elevated levels of homocysteine and lipid peroxidation in vivo", Curr Atheroscler Rep, 1, pp.87~89 (1999)
14. Misra UK, "MTHFR gene polymorphism and its relationship with plasma homocysteine and folate in a North Indian population", Biochem Genet, 48, pp.229~235 (2010)
15. Klerk M, "MTHFR 677C-->T polymorphism and risk of coronary heart disease: a meta-analysis", JAMA, 288, pp.2023~2031 (2002)
16. Brattström L, "Common methylenetetrahydrofolate reductase gene mutation leads to hyperhomocysteinemia but not to vascular disease: the result of a meta-analysis", Circulation, 98, pp.2520~2526 (1998)
17. Fux R, "Effect of acute hyperhomocysteinemia on methylation potential of erythrocytes and on DNA methylation of lymphocytes in healthy male volunteers", Am J Physiol Renal Physiol, 289, pp.F786~F792 (2005)
18. Bazzano LA, "Folic acid supplementation and cardiovascular disease: the state of the art", Am J Med Sci, 338, pp.48~49 (2009)
19. Pexa A, "Homocysteine in food", Eur Food Res Technol, 226, pp.933~935 (2008)
20. Frank J, "No evidence for prooxidative effects of homocysteine in vascular endothelial cells", Eur J Nutr, 46, pp.286~292 (2007)
21. Kelly PJ, "Management and Prevention of Stroke Associated with Elevated Homocysteine", Curr Treat Options Cardiovasc Med, 4, pp.363~371 (2002)
22. Selhub J, "Relationship between homocysteine and thrombotic disease", Am J Med Sci, 316, pp.129~141 (1998)
23. Tacconelli S, "Measurement of 8-iso-prostaglandin F2alpha in biological fluids as a measure of lipid peroxidation", Methods Mol Biol, 644, pp.165~178 (2010)
24. Kawasaki A, "Hyperhomocysteinaemia in young patients with non-arteritic anterior ischaemic optic neuropathy", Br J Ophthalmol, 83, pp.1287~1290 (1999)
25. Lim MH, "Homocysteine and pulsatility index of cerebral arteries", Stroke, 40, pp.3216~3220 (2009)
26. Sen S, "Hyperhomocysteinemia is Associated with Aortic Atheroma Progression in Stroke", TIA Patients, 2010, pp.1, 131~
27. Blasko I, "Conversion from cognitive health to mild cognitive impairment and Alzheimer’s disease: prediction by plasma amyloid beta 42, medial temporal lobe atrophy and homocysteine", Neurobiol Aging, 29, pp.1~11 (2008)
28. Moustafa AA, "The relationship between associative learning, transfer generalization, and homocysteine levels in mild cognitive impairment", PLoS One, 7, pp.e46496~ (2012)
29. Smith AD, "Homocysteine-lowering by B vitamins slows the rate of accelerated brain atrophy in mild cognitive impairment: a randomized controlled trial", PLoS One, 5, pp.e12244~ (2010)
30. Faux NG, "Homocysteine, vitamin B12, and folic acid levels in Alzheimer’s disease, mild cognitive impairment, and healthy elderly: baseline characteristics in subjects of the Australian Imaging Biomarker Lifestyle study", J Alzheimers Dis, 27, pp.909~922 (2011)
31. Blasko I, "Conversion from mild cognitive impairment to dementia: influence of folic acid and vitamin B12 use in the VITA cohort", J Nutr Health Aging, 16, pp.687~694 (2012)
32. Kim G, "Relationship of cognitive function with B vitamin status, homocysteine, and tissue factor pathway inhibitor in cognitively impaired elderly: a cross-sectional survey", J Alzheimers Dis, 33, pp.853~862 (2013)
33. Reitz C, "Plasma homocysteine and risk of mild cognitive impairment", Dement Geriatr Cogn Disord, 27, pp.11~17 (2009)
34. Annerbo S, "The significance of thyroid-stimulating hormone and homocysteine in the development of Alzheimer’s disease in mild cognitive impairment: a 6-year follow-up study", Am J Alzheimers Dis Other Demen, 21, pp.182~188 (2006)
35. Postiglione A, "Plasma folate, vitamin B(12), and total homocysteine and homozygosity for the C677T mutation of the 5,10-methylene tetrahydrofolate reductase gene in patients with Alzheimer’s dementia. A case-control study", Gerontology, 47, pp.324~329 (2001)
36. Tyagi SC, "Homocysteine in microvascular endothelial cell barrier permeability", Cell Biochem Biophys, 43, pp.37~44 (2005)
37. Kado DM, "Homocysteine versus the vitamins folate, B6, and B12 as predictors of cognitive function and decline in older high-functioning adults: MacArthur Studies of Successful Aging", Am J Med, 118, pp.161~167 (2005)
38. Ford AH, "Vitamins B(12), B(6), and folic acid for cognition in older men", Neurology, 75, pp.1540~1547 (2010)
39. Nilsson K, "Elevated plasma homocysteine level is not primarily related to Alzheimer’s disease", Dement Geriatr Cogn Disord, 34, pp.121~127 (2012)
40. Singleton AB, "The genetics of Parkinson’s disease: progress and therapeutic implications", Mov Disord, 28, pp.14~23 (2013)
41. Blesa J, "Przedborski S. Classic and new animal models of Parkinson’s disease", Biomed Biotechnol, 2012, pp.845618~ (2012)
42. Quik M, "Nicotine as a potential neuroprotective agent for Parkinson’s disease", Mov Disord, 27, pp.947~957 (2012)
43. Palacios N, "Caffeine and risk of Parkinson’s disease in a large cohort of men and women", Mov Disord, 27, pp.1276~1282 (2012)
44. Luo JJ, "Estrogen and Parkinson’s disease", Curr Trends Neurol, 5, pp.49~57 (2011)
45. AlDakheel A, "Pathogenesis-targeted, disease-modifying therapies in Parkinson disease", Neurotherapeutics, 11, pp.6~23 (2014)
46. Białecka M, "Genetic and environmental factors for hyperhomocysteinaemia and its clinical implications in Parkinson’s disease", Neurol Neurochir Pol, 43, pp.272~285 (2009)
47. Duan W, "Dietary folate deficiency and elevated homocysteine levels endanger dopaminergic neurons in models of Parkinson’s disease", J Neurochem, 80, pp.101~110 (2002)
48. Mattson MP, "Folate and homocysteine metabolism in neural plasticity and neurodegenerative disorders", Trends Neurosci, 26, pp.137~146 (2003)
49. Doherty GH, "Homocysteine and Parkinson’s disease: a complex relationship", J Neurol Disord, 1, pp.107~ (2013)
50. Brosnan JT, "Methylation demand: a key determinant of homocysteine metabolism", Acta Biochim Pol, 51, pp.405~413 (2004)
51. Zoccolella S, "Plasma homocysteine levels in Parkinson’s disease: role of antiparkinsonian medications", Parkinsonism Relat Disord, 11, pp.131~133 (2005)
52. Miller JW, "Effect of L-Dopa and the catechol-O-methyltransferase inhibitor Ro 41-0960 on sulfur amino acid metabolites in rats", Clin Neuropharmacol, 20, pp.55~66 (1997)
53. Müller T, "Nigral endothelial dysfunction, homocysteine, and Parkinson’s disease", Lancet, 354, pp.126~127 (1999)
54. Müller T, "Tolcapone decreases plasma levels of S-adenosyl-L-homocysteine and homocysteine in treated Parkinson’s disease patients", Eur J Clin Pharmacol, 62, pp.447~450 (2006)
55. Hu XW, "Elevated homocysteine levels in levodopa-treated idiopathic Parkinson’s disease: a meta-analysis", Acta Neurol Scand, 128, pp.73~82 (2013)
56. Zoccolella S, "Elevated homocysteine levels in Parkinson’s Disease: is there anything besides L-dopa treatment?", Curr Med Chem, 17, pp.213~221 (2010)
57. Martignoni E, "Homocysteine and Parkinson’s disease: a dangerous liaison?", J Neurol Sci, 257, pp.31~37 (2007)
58. Sahin S, "Increased plasma homocysteine levels in multiple sclerosis", Mult Scler, 13, pp.945~946 (2007)
59. Ramsaransing GS, "Plasma homocysteine levels in multiple sclerosis", J Neurol Neurosurg Psychiatry, 77, pp.189~192 (2006)
60. Vrethem M, "Increased plasma homocysteine levels without signs of vitamin B12 deficiency in patients with multiple sclerosis assessed by blood and cerebrospinal fluid homocysteine and methylmalonic acid", Mult Scler, 9, pp.239~245 (2003)
61. Río J, "Serum homocysteine levels in multiple sclerosis", Arch Neurol, 51, pp.1181~ (1994)
62. Ho PI, "Multiple aspects of homocysteine neurotoxicity: glutamate excitotoxicity, kinase hyperactivation and DNA damage", J Neurosci Res, 70, pp.694~702 (2002)
63. Kruman II, "Homocysteine elicits a DNA damage response in neurons that promotes apoptosis and hypersensitivity to excitotoxicity", J Neurosci, 20, pp.6920~6926 (2000)
64. Kararizou E, "Plasma homocysteine levels in patients with multiple sclerosis in the Greek population", J Chin Med Assoc, 76, pp.611~614 (2013)
65. Teunissen CE, "Serum homocysteine levels in relation to clinical progression in multiple sclerosis", J Neurol Neurosurg Psychiatry, 79, pp.1349~1353 (2008)
66. Russo C, "Hyperhomocysteinemia is associated with cognitive impairment in multiple sclerosis", J Neurol, 255, pp.64~69 (2008)
67. Smith DE, "Folic acid supplementation does not reduce intracellular homocysteine, and may disturb intracellular one-carbon metabolism", Clin Chem Lab Med, 51, pp.1643~1650 (2013)
68. Walker MC, "Changes in homocysteine levels during normal pregnancy", Am J Obstet Gynecol, 180(3 Pt 1), pp.660~664 (1999)
69. Hague WM, "Homocysteine and pregnancy", Best Pract Res Clin Obstet Gynaecol, 17, pp.459~469 (2003)
70. Vollset SE, "Plasma total homocysteine, pregnancy complications, and adverse pregnancy outcomes: the Hordaland Homocysteine study", Am J Clin Nutr, 71, pp.962~968 (2000)
71. Patel AP, "Effect of Homocysteine, Vitamin B12, Folic acid during pregnancy", NHL J Med Sci, 1, pp.27~31 (2012)
72. "How many people are affected by or are at risk for neural tube defects?" (2012)[URL]
73. Haj Mouhamed D, "Effect of cigarette smoking on plasma homocysteine concentrations", Clin Chem Lab Med, 49, pp.479~483 (2011)
74. Coker I, "Maternal and cord blood homocysteine and folic acid levels in smoking and nonsmoking pregnant women", Gynecol Obstet Invest, 71, pp.245~249 (2011)
75. MRC Vitamin Study Research Group, "Prevention of neural tube defects: results of the Medical Research Council Vitamin Study", Lancet, 338, pp.131~137 (1991)
76. Czeizel AE, "Prevention of the first occurrence of neural-tube defects by periconceptional vitamin supplementation", N Engl J Med, 327, pp.1832~1835 (1992)
77. Kapusta L, "Congenital heart defects and maternal derangement of homocysteine metabolism", J Pediatr, 135, pp.773~774 (1999)
78. Dodds L, "Effect of homocysteine concentration in early pregnancy on gestational hypertensive disorders and other pregnancy outcomes", Clin Chem, 54, pp.326~334 (2008)
79. Khosrowbeygi A, "Circulating levels of homocysteine in preeclamptic women", Bangladesh Med Res Counc Bull, 37, pp.106~109 (2011)
80. Harma M, "Correlation between maternal plasma homocysteine and zinc levels in preeclamptic women", Biol Trace Elem Res, 104, pp.97~105 (2005)
81. van der Put NM, "Mutated methylenetetrahydrofolate reductase as a risk factor for spina bifida", Lancet, 346, pp.1070~1071 (1995)
82. Hobbs CA, "Congenital heart defects, maternal homocysteine, smoking, and the 677 C>T polymorphism in the methylenetetrahydrofolate reductase gene: evaluating gene-environment interactions", Am J Obstet Gynecol, 194, pp.218~224 (2006)
83. He X, "Zinc antagonizes homocysteine-induced fetal heart defects in rats", Cardiovasc Toxicol, 9, pp.151~159 (2009)
84. Belcastro V, "Hyperhomocysteinemia in epileptic patients on new antiepileptic drugs", Epilepsia, 51, pp.274~279 (2010)
85. Belcastro V, "Antiepileptic drugs and MTHFR polymorphisms influence hyper-homocysteinemia recurrence in epileptic patients", Epilepsia, 48, pp.1990~1994 (2007)
86. Chango A, "The effect of 677C-->T and 1298A-->C mutations on plasma homocysteine and 5,10-methylenetetrahydrofolate reductase activity in healthy subjects", Br J Nutr, 83, pp.593~596 (2000)
87. Gorgone G, "Hyperhomocysteinemia in patients with epilepsy: does it play a role in the pathogenesis of brain atrophy? A preliminary report", Epilepsia, 50(Suppl 1), pp.33~36 (2009)
88. Flott-Rahmel B, "Homocysteic and homocysteine sulphinic acid exhibit excitotoxicity in organotypic cultures from rat brain", Eur J Pediatr, 157(Suppl 2), pp.S112~S117 (1998)
89. Bruce SG, "Prevalence and risk factors for neuropathy in a Canadian First Nation community", Diabetes Care, 31, pp.1837~1841 (2008)
90. Ambrosch A, "Relation between homocysteinaemia and diabetic neuropathy in patients with Type 2 diabetes mellitus", Diabet Med, 18, pp.185~192 (2001)
91. Cohen JA, "Increasing homocysteine levels and diabetic autonomic neuropathy", Auton Neurosci, 87, pp.268~273 (2001)
92. González R, "Plasma homocysteine levels are independently associated with the severity of peripheral polyneuropathy in type 2 diabetic subjects", J Peripher Nerv Syst, 17, pp.191~196 (2012)
93. Jianbo L, "Association of homocysteine with peripheral neuropathy in Chinese patients with type 2 diabetes", Diabetes Res Clin Pract, 93, pp.38~42 (2011)
94. Luo JJ, "Elevated plasma level of homocysteine is an independent risk factor for peripheral neuropathy", British J Med Med Res, 4, pp.161~169 (2014)
95. Weir DG, "Methylation deficiency causes vitamin B12-associated neuropathy in the pig", J Neurochem, 51, pp.1949~1952 (1988)
96. Cullen CE, "Hypohomocysteinemia: a potentially treatable cause of peripheral neuropathology?", Phys Med Rehabil Clin N Am, 23, pp.59~65 (2012)
97. Müller T, "Peripheral neuropathy in Parkinson’s disease: levodopa exposure and implications for duodenal delivery", Parkinsonism Relat Disord, 19, pp.501~507 (2013)

관련 논문AI추천